ID: ALA3968348

Max Phase: Preclinical

Molecular Formula: C33H27BrN6O

Molecular Weight: 603.52

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  Cc1ccccc1NC(=O)Cn1cc(Cn2c(-c3ccc(Br)cc3)nc(-c3ccccc3)c2-c2ccccc2)nn1

Standard InChI:  InChI=1S/C33H27BrN6O/c1-23-10-8-9-15-29(23)35-30(41)22-39-20-28(37-38-39)21-40-32(25-13-6-3-7-14-25)31(24-11-4-2-5-12-24)36-33(40)26-16-18-27(34)19-17-26/h2-20H,21-22H2,1H3,(H,35,41)

Standard InChI Key:  XGLNYNMSVRQSKG-UHFFFAOYSA-N

Associated Targets(Human)

Alpha glucosidase 860 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Oligo-1,6-glucosidase 218 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 603.52Molecular Weight (Monoisotopic): 602.1430AlogP: 7.23#Rotatable Bonds: 8
Polar Surface Area: 77.63Molecular Species: NEUTRALHBA: 6HBD: 1
#RO5 Violations: 2HBA (Lipinski): 7HBD (Lipinski): 1#RO5 Violations (Lipinski): 2
CX Acidic pKa: 13.40CX Basic pKa: 4.45CX LogP: 7.75CX LogD: 7.75
Aromatic Rings: 6Heavy Atoms: 41QED Weighted: 0.20Np Likeness Score: -1.67

References

1. Wang G, Peng Z, Wang J, Li J, Li X..  (2016)  Synthesis and biological evaluation of novel 2,4,5-triarylimidazole-1,2,3-triazole derivatives via click chemistry as α-glucosidase inhibitors.,  26  (23): [PMID:27810241] [10.1016/j.bmcl.2016.10.057]
2. Dhameja M, Gupta P..  (2019)  Synthetic heterocyclic candidates as promising α-glucosidase inhibitors: An overview.,  176  [PMID:31112894] [10.1016/j.ejmech.2019.04.025]

Source